Correlates of independent HIV-1 replication in the CNS and of its control by antiretrovirals
- 13 August 2002
- journal article
- research article
- Published by Wolters Kluwer Health in Neurology
- Vol. 59 (3) , 342-347
- https://doi.org/10.1212/wnl.59.3.342
Abstract
Objective: To investigate in detail factors associated with independent replication of HIV-1 in CNS, and to predict its therapeutic control. Methods: HIV RNA concentration was measured by PCR in 134 cross-sectional paired plasma and CSF samples from 95 patients infected with HIV-1 with various conditions, and in longitudinal CSF samples from 50 patients on antiretroviral treatment. Monocyte chemotactic protein (MCP)-1 was quantified in CSF by ELISA. Results: High HIV RNA levels either in plasma or in CSF did not correlate with HIV RNA concentration in the paired biologic sample. A high CSF-to-plasma HIV RNA ratio, suggesting independent viral replication in the CNS, was associated with higher CSF viral load and higher CSF MCP-1 levels. Higher MCP-1 levels in the CSF were also associated with neurologic disorders and were not influenced by the use of highly active antiretroviral therapy (HAART). A higher number of antiretroviral drugs with CSF penetration correlated with a more profound CSF HIV-1 load reduction, independently from the use of HAART alone. Virologic suppression in CSF was predicted by a higher number of CSF-penetrating antiretrovirals and by the baseline CSF viral load, whereas lower baseline CD4 counts and higher MCP-1 levels were associated with increased risk of virologic failure. Conclusions: Quantification of HIV RNA in CSF is clinically useful, particularly in patients with neurologic disorders. CSF penetration of antiretrovirals must be considered when choosing treatments, mainly in patients with higher CSF viral loads, advanced disease, and CNS disorders associated with significant macrophage activation.Keywords
This publication has 33 references indexed in Scilit:
- Pathways to neuronal injury and apoptosis in HIV-associated dementiaNature, 2001
- Increasing Cerebrospinal Fluid Chemokine Concentrations Despite Undetectable Cerebrospinal Fluid HIV RNA in HIV-1–Infected Patients Receiving Antiretroviral TherapyJAIDS Journal of Acquired Immune Deficiency Syndromes, 2000
- Immunological, virological and clinical response to highly active antiretroviral therapy treatment regimens in a complete clinic populationAIDS, 2000
- Antiretroviral Resistance Mutations in Human Immunodeficiency Virus Type 1 Reverse Transcriptase and Protease from Paired Cerebrospinal Fluid and Plasma SamplesThe Journal of Infectious Diseases, 2000
- Cerebrospinal Fluid Human Immunodeficiency Virus Type 1 (HIV‐1) Suppression and Efavirenz Drug Concentrations in HIV‐1–Infected Patients Receiving Combination TherapyThe Journal of Infectious Diseases, 1999
- Relationship between human immunodeficiency virus—associated dementia and viral load in cerebrospinal fluid and brainAnnals of Neurology, 1997
- Decay characteristics of HIV-1-infected compartments during combination therapyNature, 1997
- Diagnosis of AIDS-related focal brain lesionsNeurology, 1997
- Selective Elevation of Monocyte Chemotactic Protein-1 in the Cerebrospinal Fluid of AIDS Patients with Cytomegalovirus EncephalitisThe Journal of Infectious Diseases, 1996
- EXPRESSION OF HUMAN IMMUNODEFICIENCY VIRUS ANTIGEN (HIV-Ag) IN SERUM AND CEREBROSPINAL FLUID DURING ACUTE AND CHRONIC INFECTIONThe Lancet, 1986